Celltrion launches biosimilar Avtozma in 3 European markets - Yonhap News Agency
SEOUL, Jan. 30 (Yonhap) -- Celltrion Inc., a major South Korean biopharmaceutical company, said Friday it has launched its biosimilar Avtozma for the treatment of autoimmune diseases in three European countries.
/https%3A%2F%2Fvms-network-images-prod.s3-ap-southeast-2.amazonaws.com%2F2022%2F04%2F421835%2Fpickerimage.jpg)










